Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
Study Identifier:
ALX-HPP-503
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: asfotase alfa
Date
Nov 2019 - Apr 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 99 Years
Requirements Information
Sex
Female & Male
Age
18 - 99 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: asfotase alfa
Date
Nov 2019 - Apr 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 99 Years years
Requirements Information
Protocol Summary
This observational study will evaluate the treatment effect of Strensiq (asfotase alfa) on Patient Reported Outcomes (PROs) in participants diagnosed with pediatric-onset hypophosphatasia (HPP) registered in the patient support program managed by OneSource™.
Trial Locations
Location
Status
Location
Xcenda, LLC
Palm Harbor, Florida, United States, 34685
Status
N/A